Retevmo (selpercatinib) was approved in May 2020 for the treatment of RET fusion-positive NSCLC, RET-mutant medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancer. This evidence concerns the gene RET and thyroid gland carcinoma.